Literature DB >> 30390009

Creatine kinase pathway inhibition alters GSK3 and WNT signaling in EVI1-positive AML.

Lina Benajiba1,2,3, Gabriela Alexe1,2,4, Angela Su5, Emmanuel Raffoux6, Jean Soulier6, Michael T Hemann7, Olivier Hermine3, Raphael Itzykson5,6, Kimberly Stegmaier8,9, Alexandre Puissant10.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30390009      PMCID： PMC6596421          DOI： 10.1038/s41375-018-0291-x

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  14 in total

1.  The creatine kinase pathway is a metabolic vulnerability in EVI1-positive acute myeloid leukemia.

Authors:  Nina Fenouille; Christopher F Bassil; Issam Ben-Sahra; Lina Benajiba; Gabriela Alexe; Azucena Ramos; Yana Pikman; Amy S Conway; Michael R Burgess; Qing Li; Frédéric Luciano; Patrick Auberger; Ilene Galinsky; Daniel J DeAngelo; Richard M Stone; Yi Zhang; Archibald S Perkins; Kevin Shannon; Michael T Hemann; Alexandre Puissant; Kimberly Stegmaier
Journal:  Nat Med       Date:  2017-02-13       Impact factor: 53.440

2.  Glycogen synthase kinase 3 in MLL leukaemia maintenance and targeted therapy.

Authors:  Zhong Wang; Kevin S Smith; Mark Murphy; Obdulio Piloto; Tim C P Somervaille; Michael L Cleary
Journal:  Nature       Date:  2008-09-17       Impact factor: 49.962

3.  Glycogen synthase kinase-3 is an in vivo regulator of hematopoietic stem cell repopulation.

Authors:  Jennifer J Trowbridge; Anargyros Xenocostas; Randall T Moon; Mickie Bhatia
Journal:  Nat Med       Date:  2005-12-11       Impact factor: 53.440

4.  GSK-3 promotes conditional association of CREB and its coactivators with MEIS1 to facilitate HOX-mediated transcription and oncogenesis.

Authors:  Zhong Wang; Masayuki Iwasaki; Francesca Ficara; Chenwei Lin; Christina Matheny; Stephen H K Wong; Kevin S Smith; Michael L Cleary
Journal:  Cancer Cell       Date:  2010-06-15       Impact factor: 31.743

5.  AZD1080, a novel GSK3 inhibitor, rescues synaptic plasticity deficits in rodent brain and exhibits peripheral target engagement in humans.

Authors:  Biljana Georgievska; Johan Sandin; James Doherty; Anette Mörtberg; Jan Neelissen; Anita Andersson; Susanne Gruber; Yvonne Nilsson; Pär Schött; Per I Arvidsson; Sven Hellberg; Gunilla Osswald; Stefan Berg; Johanna Fälting; Ratan V Bhat
Journal:  J Neurochem       Date:  2013-03-11       Impact factor: 5.372

6.  GSK3 is a regulator of RAR-mediated differentiation.

Authors:  K Gupta; F Gulen; L Sun; R Aguilera; A Chakrabarti; J Kiselar; M K Agarwal; D N Wald
Journal:  Leukemia       Date:  2012-01-06       Impact factor: 11.528

7.  The intersection of genetic and chemical genomic screens identifies GSK-3α as a target in human acute myeloid leukemia.

Authors:  Versha Banerji; Stacey M Frumm; Kenneth N Ross; Loretta S Li; Anna C Schinzel; Cynthia K Hahn; Rose M Kakoza; Kwan T Chow; Linda Ross; Gabriela Alexe; Nicola Tolliday; Haig Inguilizian; Ilene Galinsky; Richard M Stone; Daniel J DeAngelo; Giovanni Roti; Jon C Aster; William C Hahn; Andrew L Kung; Kimberly Stegmaier
Journal:  J Clin Invest       Date:  2012-02-13       Impact factor: 14.808

8.  2-Deoxy-D-glucose cooperates with arsenic trioxide to induce apoptosis in leukemia cells: involvement of IGF-1R-regulated Akt/mTOR, MEK/ERK and LKB-1/AMPK signaling pathways.

Authors:  María Cristina Estañ; Eva Calviño; Elena de Blas; María del Carmen Boyano-Adánez; Maria Luz Mena; Milagros Gómez-Gómez; Eduardo Rial; Patricio Aller
Journal:  Biochem Pharmacol       Date:  2012-10-05       Impact factor: 5.858

9.  Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation.

Authors:  Fang Wang; Jeremy Travins; Byron DeLaBarre; Virginie Penard-Lacronique; Stefanie Schalm; Erica Hansen; Kimberly Straley; Andrew Kernytsky; Wei Liu; Camelia Gliser; Hua Yang; Stefan Gross; Erin Artin; Veronique Saada; Elena Mylonas; Cyril Quivoron; Janeta Popovici-Muller; Jeffrey O Saunders; Francesco G Salituro; Shunqi Yan; Stuart Murray; Wentao Wei; Yi Gao; Lenny Dang; Marion Dorsch; Sam Agresta; David P Schenkein; Scott A Biller; Shinsan M Su; Stephane de Botton; Katharine E Yen
Journal:  Science       Date:  2013-04-04       Impact factor: 63.714

Review 10.  Multifaceted roles of GSK-3 and Wnt/β-catenin in hematopoiesis and leukemogenesis: opportunities for therapeutic intervention.

Authors:  J A McCubrey; L S Steelman; F E Bertrand; N M Davis; S L Abrams; G Montalto; A B D'Assoro; M Libra; F Nicoletti; R Maestro; J Basecke; L Cocco; M Cervello; A M Martelli
Journal:  Leukemia       Date:  2013-06-19       Impact factor: 11.528
View more
  3 in total

Review 1.  Creatine metabolism: energy homeostasis, immunity and cancer biology.

Authors:  Lawrence Kazak; Paul Cohen
Journal:  Nat Rev Endocrinol       Date:  2020-06-03       Impact factor: 43.330

2.  MiR-27a-3p Targeting GSK3β Promotes Triple-Negative Breast Cancer Proliferation and Migration Through Wnt/β-Catenin Pathway.

Authors:  Ruizhen Wu; Bingqing Zhao; Xunxin Ren; Shiheng Wu; Mingzao Liu; Zipeng Wang; Wei Liu
Journal:  Cancer Manag Res       Date:  2020-07-24       Impact factor: 3.989

3.  Propofol suppresses adipose-derived stem cell progression via PI3K/AKT-Wnt signaling pathway.

Authors:  Guoping Yin; Jia Wang; Yanling Zhong; Weidong Wu
Journal:  BMC Anesthesiol       Date:  2022-03-09       Impact factor: 2.217
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.